|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM063516934 |
003 |
DE-627 |
005 |
20231221223846.0 |
007 |
tu |
008 |
231221s1984 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0212.xml
|
035 |
|
|
|a (DE-627)NLM063516934
|
035 |
|
|
|a (NLM)6374678
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Jokinen, K
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Flupenthixol versus diazepam in the treatment of psychosomatic disorders
|b a double-blind, multi-centre trial in general practice
|
264 |
|
1 |
|c 1984
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 29.06.1984
|
500 |
|
|
|a Date Revised 21.11.2013
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a In a Finnish general practice 120 patients with psychosomatic disorders, manifest as syndromes of tension headache, cardiac neurosis, dizziness or muscular tension, were randomly allocated to treatment over a 4-week period with either flupenthixol (1 to 2 mg per day) or diazepam (5 to 10 mg mg per day). The 4 syndromes and 12 associated symptoms (anxiety, fatigue, depression, pain, asthenia, muscle fatiguability, tension, dyspnoea, restlessness, palpitations, sleep disorders, and vertigo) were rated on a 4-point scale on entry, at 2 weeks and at 4 weeks. Both drugs reduced significantly the average total scores for syndromes and single symptoms after 2-weeks' treatment. Flupenthixol was the more effective in relieving fatigue and vertigo; diazepam in relieving headache, anxiety, tension, restlessness and sleep disturbance. Cardiac neurosis, palpitations and general muscular tension responded poorly to both drugs. After 4 weeks, relief of vertigo, pain and fatigue was more evident in the flupenthixol group, and of anxiety, tension and restlessness in the diazepam group. Side-effects were complained of at some stage by 17 patients in the flupenthixol group (9 of fatigue, 5 of sleep disturbance, 1 of constipation, 1 of extrapyramidal symptoms, and 1 of weight gain) and by 16 patients in the diazepam group (10 of fatigue, 4 of sleep problems and 2 of diarrhoea)
|
650 |
|
4 |
|a Clinical Trial
|
650 |
|
4 |
|a Comparative Study
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Randomized Controlled Trial
|
650 |
|
7 |
|a Thioxanthenes
|2 NLM
|
650 |
|
7 |
|a Flupenthixol
|2 NLM
|
650 |
|
7 |
|a FA0UYH6QUO
|2 NLM
|
650 |
|
7 |
|a Diazepam
|2 NLM
|
650 |
|
7 |
|a Q3JTX2Q7TU
|2 NLM
|
700 |
1 |
|
|a Koskinen, T
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Selonen, R
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 9 vom: 14., Seite 573-81
|w (DE-627)NLM023961570
|
773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:9
|g day:14
|g pages:573-81
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 3
|j 1984
|e 9
|b 14
|h 573-81
|